Abstract
Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on efficacy and safety.Existing data were evaluated by a steering committee and subsequently reviewed...
Description
Keywords
Rheumatoid/drug therapy/immunology , INTERLEUKIN-6 , Piperidines/therapeutic use , RESPONSE , Pyridines , Clinical sciences , Antirheumatic Agents/therapeutic use , Adamantane , Psoriasis/drug therapy/immunology , THERAPY , Arthritis, Rheumatoid , DOUBLE-BLIND , Psoriatic/drug therapy/immunology , Pyrazoles/therapeutic use , Piperidines , Heterocyclic Compounds , info:eu-repo/classification/ddc/616 , Medicine and Health Sciences , Purines/therapeutic use , RECEPTOR INHIBITION , Pyridines/therapeutic use , ddc:616 , Public health , Adamantane/analogs & derivatives/therapeutic use , Inflammatory Bowel Diseases/drug therapy/immunology , Europe , EULAR RECOMMENDATIONS , Antirheumatic Agents , Combination , 3-Ring/therapeutic use , Niacinamide/analogs & derivatives/therapeutic use , Cytokines , Spondylarthropathies/drug therapy/immunology , Drug Therapy, Combination , Ankylosing/drug therapy/immunology , Triazoles/therapeutic use , Heterocyclic Compounds, 3-Ring , Niacinamide , Immunology , Advisory Committees , Therapeutics , INADEQUATE , Azetidines/therapeutic use , Autoimmune Diseases , HERPES-ZOSTER , Cytokines/immunology , Drug Therapy , Rheumatology , Health services and systems , Humans , Janus Kinase Inhibitors , Psoriasis , ACTIVE PSORIATIC-ARTHRITIS , Inflammation , VENOUS THROMBOEMBOLISM , Arthritis , Janus Kinase Inhibitors/therapeutic use , Arthritis, Psoriatic , Pyrimidines/therapeutic use , Sulfonamides/therapeutic use , Recommendation , Inflammatory Bowel Diseases , RHEUMATOID-ARTHRITIS , MAINTENANCE , Pyrimidines , Purines , MODIFYING ANTIRHEUMATIC DRUGS , Azetidines , Pyrazoles , Spondylitis